688271 联影医疗
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入6,015,90112.79%10,300,10411,410,7669,238,1237,253,756
减:营业总成本5,075,10111.18%9,385,2729,857,9467,774,1816,004,198
    其中:营业成本3,132,66415.65%5,300,1626,039,1594,769,9983,668,599
               财务费用(49,617)-24.07%(112,290)(148,887)(98,725)(24,430)
               资产减值损失(198)-100.50%13,843(42,886)(74,747)(25,198)
公允价值变动收益(45,441)-713.21%37,000(6,063)28,500(10,588)
投资收益39,841-11.53%98,074110,34512,66762,250
    其中:对联营企业和合营企业的投资收益(1,074)-84.23%(5,623)(15,872)(7,651)(3,055)
营业利润1,076,9303.53%1,366,3562,141,5151,928,2431,696,132
利润总额1,072,9723.19%1,351,7082,142,2551,919,7951,697,543
减:所得税费用85,076-10.66%109,784164,500269,710294,033
净利润987,8964.59%1,241,9241,977,7551,650,0861,403,509
减:非控股权益(10,122)79.26%(19,945)3,462(5,998)(13,675)
股东净利润998,0185.03%1,261,8691,974,2921,656,0841,417,185

市场价值指针
每股收益 (元) *1.2104.31%1.5402.4002.1901.960
每股派息 (元) *0.1308.33%0.2000.2500.201--
每股净资产 (元) *25.2306.16%24.15022.89221.2146.960
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容